Category: Include on Menu
-
Hain Celestial Reports FY2026 Results as North America Margins Improve
Hain Celestial reported lower fiscal 2026 sales and adjusted EBITDA, while fourth-quarter North America organic growth, margin expansion and stronger free cash flow highlighted progress ahead of the planned sale of its International business. Key Investor Takeaways Why HAIN Stock Is in Focus Hain Celestial’s fiscal 2026 results showed a business that became smaller following…
-
Why a Major Gold Producer Invested $5.4M Before Phenom’s First Drill Hole
In exploration, a promising gold target is one thing. Having a major gold producer invest before you’ve even drilled the first hole is quite another. Hello, I’m Ricki Lee, and this is The Capital Compass. Today we’re looking at Phenom Resources (USOTC:PHNMF) (TSXV:PHNM), a Nevada-focused explorer with exposure to both gold and vanadium — but…
-
BioNTech Shares Rise 6.4% After Updated Gotistobart Lung Cancer Trial Data
BioNTech SE (NASDAQ:BNTX) shares rose 6.4% in pre-market trading on Monday after the company reported updated survival data from stage 1 of the Phase 3 PRESERVE-003 trial evaluating gotistobart in patients with squamous non-small cell lung cancer. Gotistobart produced median overall survival of 18.5 months, compared with 10.0 months for standard-of-care docetaxel chemotherapy in patients…
-
Oracle Begins New Round of Job Cuts as AI Infrastructure Spending Rises – Report
Oracle Corp (NYSE:ORCL) has begun another round of job cuts, Business Insider reported on Monday, citing three affected employees and an email obtained by the publication. The layoffs began on Monday, in line with expectations from a source familiar with the matter, according to the report. An Oracle spokesperson had not responded to a request…
-
Cullinan Therapeutics Shares Fall 6.3% After Phase 3 Zipalertinib Trial Results
Cullinan Therapeutics (NASDAQ:CGEM) shares fell 6.3% on Monday after the company and its partners reported Phase 3 results for zipalertinib in patients with a form of non-small cell lung cancer. Cullinan, Taiho Oncology and Taiho Pharmaceutical said the REZILIENT3 trial met its primary endpoint, with zipalertinib plus chemotherapy extending median progression-free survival by 6.0 months…
-
Ainos Shares Rise 6.9% After Receiving Initial AI Nose Semiconductor Orders
Ainos Inc. (NASDAQ:AIMD) shares rose 6.9% in pre-market trading on Monday after the company said it received initial commercial orders for its AI Nose platform from a front-end semiconductor manufacturer. The orders follow technical validation activities involving approximately 200 AI Nose systems deployed at wafer fabrication facilities since March. Ainos said the new orders represent…
-
Quantum Computing Inc. Signs Three-Year Agreement With Hamad Bin Khalifa University
Quantum Computing Inc. (NASDAQ:QUBT) has entered into a three-year framework agreement with Hamad Bin Khalifa University in Qatar covering collaboration in quantum computing, quantum sensing and quantum communications. The agreement includes joint academic research, executive education programmes, industry-focused projects, application development and co-marketing activities. Financial terms were not disclosed. QCi to Provide Access to Dirac-3…
-
Mobilicom Receives Follow-On Ground Control Station Order From Asian Customer
Mobilicom Limited (NASDAQ:MOB) said it received a follow-on production order for its Mobile Ground Control Stations from an Asia-based conglomerate that manufactures robotics platforms for military and industrial applications. The value and other financial terms of the order were not disclosed. Customer Has Ordered Across Three Mobilicom Product Families According to Mobilicom, the unnamed customer…
-
Nasdaq Leads US Stocks Lower as AI Development Debate Weighs on Technology Sector: Dow Jones, S&P, Wall Street
US stocks opened lower on Monday, led by declines in technology shares after several artificial intelligence industry executives called for a slowdown in the development of advanced AI models. At 09:32 ET (13:32 GMT), the S&P 500 was down 0.7% at 7,603.80 points, while the NASDAQ Composite fell 1.6% to 28,902.20. The Dow Jones Industrial…
-
Armata Pharmaceuticals Shares Rise 8% After FDA Grants AP-SA02 Breakthrough Therapy Designation
Armata Pharmaceuticals (AMEX:ARMP) shares rose 8% after the company said the US Food and Drug Administration granted Breakthrough Therapy designation to AP-SA02, its intravenously administered Staphylococcus aureus multi-phage product candidate. The designation covers AP-SA02 as an adjunct treatment for complicated bacteremia caused by methicillin-sensitive S. aureus, or MSSA, and methicillin-resistant S. aureus, or MRSA. FDA…